Abstract Purpose of Review Despite its promise as an HIV prevention strategy, PrEP uptake
remains slow, especially among highest priority populations. One factor that may be …

Introduction Adolescent girls and young women (AGYW) in Africa have high HIV incidence
despite scale‐up of HIV testing and HIV treatment. Placebo‐controlled trials of tenofovir …

More than a decade after the first efficacy evidence for oral HIV pre-exposure prophylaxis
(PrEP) was reported, PrEP uptake globally has been inadequate and global HIV prevention …

Background Previous systematic reviews have identified a high prevalence of HIV infection
in transgender women in the USA and in those who sell sex (compared with both female …

In sub-Saharan Africa, adolescent girls and young women (AGYW) are 5 to 14 times more
likely to be infected with HIV than their male peers. Every day, more than 750 AGYW are …

Background Preexposure prophylaxis with antiretroviral agents has been shown to reduce
the transmission of human immunodeficiency virus (HIV) among men who have sex with …

Background Antiretroviral preexposure prophylaxis is a promising approach for preventing
human immunodeficiency virus type 1 (HIV-1) infection in heterosexual populations …

Background Preexposure prophylaxis with antiretroviral drugs has been effective in the
prevention of human immunodeficiency virus (HIV) infection in some trials but not in others …

Importance About 40 000 Americans and 2 million people worldwide are newly infected with
HIV each year. The combination antiretroviral regimen, tenofovir disoproxil fumarate …

Introduction HIV‐related stigma and discrimination continue to hamper efforts to prevent new
infections and engage people in HIV treatment, care and support programmes. The …